Innova Captab Ltd

Stage 3 · Topping · week 1⚠ 2→3 today

As of 20 Nov 2026, Innova Captab is in Stage 3, the topping phase, now in its first week (since 20 Nov 2026). It closed at ₹978, 24.6% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. More about the company

₹977.8
Close, 20 Nov 2026
-2.74% on the day
₹5,595 Cr · Mid cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

RS rank

Edge

—

INNOVACAP's uptrend is tiring: in its first week into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.

Its relative strength is 85 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Is INNOVACAP early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-12-29 → 2026-11-20
S? 43w
S2 16w
S4 28w
S2 25w
2023-12-292026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 43w → S2 16w → S3 11w → S4 2w → S1 1w → S2 4w → S1 2w → S4 5w → S1 8w → S4 28w → S1 6w → S2 25w → S3 1w current
Total tracked: 150 weeks across 13 stage runs.

INNOVACAP among Pharmaceuticals36th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…36INNOVACAPStage 3 · wk 185−0.2%
vs 52W High
-24.6%
₹642.8 lo₹1,297.6 hi
24.6% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 1
1w13w26w
Week 1, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
6.8%
200 DMA: ₹915.2 · rising
The stock still holds above its 200-day average, but the trend has flattened. A close below the line would add to the Stage 4 risk.
Rel Volume
0.60x
vs 50-day avg
Volume was well below average. Quiet sessions say little in a topping stock. Volume on the down days matters more.
Trend Health
↗
Short-term trend rising gently
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-0.2%
3M
-6.0%
6M
+11.1%
YTD
+36.2%
1Y
+34.3%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Industry has 48 Stage 2 leaders. See Pharmaceuticals Stage 2 →

Mutual fund holdings

Held by 9 mutual funds in portfolios to October 2026: 5 active funds and 4 index funds and ETFs.

In October, no active fund changed its holding.

Largest active holders, by weight in the fund
All 9 funds and what each did in October

Mutual funds holding INNOVACAP: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 9 Oct 2026
Last appeared 28 Aug 2026
Last appeared 1 Jun 2026
14 appearances in the last 60 days.
Recent Stage Timeline
2026-11-20S32→3
Wk 1 · Vol 0.60x
2026-11-19S2
Wk 24 · Vol 0.73x
2026-11-18S2
Wk 24 · Vol 1.43x
2026-11-17S2
Wk 24 · Vol 1.60x
2026-11-16S2
Wk 24 · Vol 4.65x
2026-11-13S2
Wk 23 · Vol 1.00x
2026-11-12S2
Wk 23 · Vol 1.28x
2026-11-11S2
Wk 23 · Vol 0.60x
2026-11-09S2
Wk 23 · Vol 0.85x
2026-11-06S2
Wk 23 · Vol 0.19x
2026-11-05S2
Wk 22 · Vol 0.48x
2026-11-04S2
Wk 22 · Vol 0.62x
Moving averages & range
50 DMA
₹1,104.6
200 DMA
₹915.2
52W High
₹1,297.6
52W Low
₹642.8
5D Low
₹977.8
Resistance levels (recent highs)
20d High
₹1,172.4
60d High
₹1,297.6
120d High
₹1,297.6
250d High
₹1,297.6
Next resistance
+19.9%
to 20d High
P/E (TTM)
43.6
Forward 25.9
Earnings Growth (YoY)
+42.3%
Revenue +33.9%
ROE
+13.7%
Profit margin +8.8%
Dividend Yield
0.17%
P/B 6.2

Innova Captab: quick answers

What stage is Innova Captab in?

As of 20 Nov 2026, Innova Captab (INNOVACAP) is in Stage 3, the topping phase. It entered Stage 3 on 20 Nov 2026 and is in its first week there. What the four stages mean

Is Innova Captab in an uptrend?

Its uptrend has stalled. Innova Captab is in Stage 3, the topping phase that follows an advance. It trades 6.8% above its 200-day average, which is rising.

How far is Innova Captab from its 52-week high?

Innova Captab closed at ₹978 on 20 Nov 2026, 24.6% below its 52-week high of ₹1,298. Its 52-week low is ₹643.

How has Innova Captab performed over the past year?

As of 20 Nov 2026, Innova Captab is up 34.3% over the past year and up 36.2% so far in 2026.

Which sector and industry is Innova Captab in?

Innova Captab is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.